



## Porcine Models of Neurotrauma and Neurological Disorders

Guest Editors:

### Dr. John O'Donnell

1. Center for Brain Injury and Repair, Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

2. Center for Neurotrauma, Neurodegeneration and Restoration, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA

### Dr. Dmitry Petrov

Center for Brain Injury and Repair, Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

### Message from the Guest Editors

Translation from lab to clinic has a dismal record in the fields of neurotrauma and neurological disorders. This is due in part to the challenging heterogeneity of the clinical population common to all translational research, but it is also due to the unique challenges of recreating the mechanisms and manifestations of human neurological injury/disorders in small animals. Large IND/IDE enabling animal models are an essential component of successful pipelines for moving discoveries from bench to bedside in other fields, and neuroscience has made significant progress toward establishing such pipelines in its many unique subfields. Due to their size, neuroanatomy, and other factors, swine have proven to be ideal for providing high-fidelity, clinically relevant studies to bridge the gap between small animals and humans. Herein, we provide detailed descriptions of the sophisticated swine model systems that have been developed to empower translational research in neurotrauma and neurological disorders.

Deadline for manuscript submissions:

**closed (31 May 2023)**





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding

Rehabilitation Hospital and

Massachusetts General Hospital,

Harvard Medical School, Boston,

MA 02114, USA

2. Department of Epidemiology,

Harvard T.H. Chan School of

Public Health, Boston, MA 02115,

USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)